Novocure Ltd (NASDAQ: NVCR) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
17.51
+1.12+6.83%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -1.30 | Insider Own | 3.62% | Shs Outstand | 116.45M | Perf Week | 10.44% |
| Market Cap | 1.91B | Forward P/E | - | EPS next Y | -0.82 | Insider Trans | -5.45% | Shs Float | 95.84M | Perf Month | -5.21% |
| Enterprise Value | 2.05B | PEG | - | EPS next Q | -0.23 | Inst Own | - | Short Float | 11.96% | Perf Quarter | -2.61% |
| Income | -149.06M | P/S | 2.73 | EPS this Y | 3.79% | Inst Trans | - | Short Ratio | 6.66 | Perf Half Y | 62.44% |
| Sales | 699.19M | P/B | 5.62 | EPS next Y | 34.73% | ROA | -18.68% | Short Interest | 11.46M | Perf YTD | 26.76% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -44.00% | 52W High | 22.92 -23.59% | Perf Year | 43.90% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -26.15% | 52W Low | 10.49 66.90% | Perf 3Y | -45.53% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 6.78% 5.80% | Gross Margin | 76.13% | Volatility | 4.54% 6.15% | Perf 5Y | -89.36% |
| Dividend TTM | - | EV/Sales | 2.93 | EPS Y/Y TTM | 16.67% | Oper. Margin | -22.08% | ATR (14) | 1.08 | Perf 10Y | 102.60% |
| Dividend Ex-Date | - | Quick Ratio | 2.70 | Sales Y/Y TTM | 15.54% | Profit Margin | -21.25% | RSI (14) | 51.22 | Recom | 2.47 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.89 | EPS Q/Q | 63.89% | SMA20 | 1.33% | Beta | 1.03 | Target Price | 26.00 |
| Payout | 0.00% | Debt/Eq | 0.69 | Sales Q/Q | 15.72% | SMA50 | 0.25% | Rel Volume | 0.89 | Prev Close | 16.39 |
| Employees | 1,605 | LT Debt/Eq | 0.82 | Earnings | Oct 29 | SMA200 | 18.44% | Avg Volume | 1.71M | Price | 17.51 |
| IPO Date | Oct 02, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 60.79% 6.46% | Net Debt/EBITDA | -1.04 | Volume | 1,529,194 | Change | 6.83% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-24-26 | Reiterated | Wedbush | Neutral | $20 |
| Jul-23-26 | Reiterated | H.C. Wainwright | Buy | $46 → $52 |
| Jun-18-26 | Reiterated | HC Wainwright & Co. | Buy | $47 → $46 |
| Feb-12-26 | Reiterated | HC Wainwright & Co. | Buy | $39 → $47 |
| Jan-13-26 | Reiterated | HC Wainwright & Co. | Buy | $42 → $39 |
| Jan-05-26 | Reiterated | Evercore ISI | Outperform | $22 → $20 |
| Oct-30-25 | Reiterated | HC Wainwright & Co. | Buy | $30 → $42 |
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight | $15 |
| Dec-02-24 | Upgrade | Evercore ISI Group | In Line → Outperform | $15 → $30 |
| Oct-16-24 | Upgrade | HC Wainwright & Co. | Neutral → Buy | $24 → $30 |
Latest News
Aug-07-26
Jul-27-26
11:03AM
Jul-24-26
10:21AM
Jul-23-26
01:00PM
NovoCure Limited (NVCR) Q2 2026 Earnings Call Transcriptseekingalpha.com
09:16AM
09:08AM
NovoCure Q2 Earnings Call Highlightsmarketbeat.com
08:00AM
Jul-16-26
Jul-16-2611:06AM
10:00AM
Jul-14-26
Jul-14-2606:24PM
Jul-13-26
Company
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 699 | 655 | 605 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 167 | 167 | 137 | — | — | — | — | — | — | |
| Gross Profit | 531 | 488 | 468 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 462 | 418 | 429 | — | — | — | — | — | — | |
| Research and Development | 224 | 225 | 210 | — | — | — | — | — | — | |
| Other Operating Expense | 1 | -1 | 0 | — | — | — | — | — | — | |
| Operating Income | -154 | -154 | -170 | — | — | — | — | — | — | |
| Interest Expense | 3 | 0 | 12 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 4 | 18 | 51 | — | — | — | — | — | — | |
| Net Income Before Taxes | -152 | -136 | -131 | — | — | — | — | — | — | |
| Income Taxes | -4 | 0 | 37 | — | — | — | — | — | — | |
| Consolidated Net Income | -148 | -136 | -169 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -148 | -136 | -169 | — | — | — | — | — | — | |
| Net Income | -148 | -136 | -169 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.30 | -1.22 | -1.56 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.30 | -1.22 | -1.56 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.30 | -1.22 | -1.56 | — | — | — | — | — | — | |
| EBITDA | -134 | -119 | -110 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.91 | 2.19 | 5.32 | — | — | — | — | — | — | |
| Gross Margin | 75.97 | 74.50 | 77.36 | — | — | — | — | — | — | |
| Operating Margin | -22.03 | -23.51 | -28.10 | — | — | — | — | — | — | |
| Net Margin | -21.17 | -20.76 | -27.93 | — | — | — | — | — | — | |
| Shares Outstanding | 116 | 111 | 108 | — | — | — | — | — | — | |
| Market Capitalization | 2,031 | 1,435 | 3,218 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Leonard Frank X | Chief Executive Officer | Jun 04 '26 | Sale | 17.93 | 34,273 | 614,635 | 459,520 | Jun 05 |
| Stafford Kristin | Director | Jun 02 '26 | Sale | 15.77 | 2,945 | 46,445 | 11,324 | Jun 03 |
| Scannell Timothy J | Director | Jun 02 '26 | Sale | 15.77 | 2,945 | 46,445 | 14,288 | Jun 03 |
| LEUNG GABRIEL | Director | Jun 02 '26 | Sale | 15.77 | 2,945 | 46,445 | 89,499 | Jun 03 |
| Ocean Allyson J | Director | Jun 02 '26 | Sale | 15.77 | 2,945 | 46,445 | 11,324 | Jun 03 |
| HILLEMAN JERYL L | Director | Jun 02 '26 | Sale | 15.77 | 2,945 | 46,445 | 13,861 | Jun 03 |
| VERNON W ANTHONY | Director | Jun 02 '26 | Sale | 15.77 | 2,945 | 46,445 | 197,657 | Jun 03 |
| Hung David | Director | Jun 02 '26 | Sale | 15.77 | 2,945 | 46,445 | 20,465 | Jun 03 |
| VERNON W ANTHONY | Director | Apr 28 '26 | Option Exercise | 11.39 | 21,500 | 244,885 | 200,602 | Apr 28 |
| Paravasthu Mukund | Chief Operating Officer | Mar 05 '26 | Sale | 13.77 | 43,246 | 595,670 | 72,832 | Mar 05 |
| Brackmann Christoph | Chief Financial Officer | Mar 04 '26 | Sale | 13.31 | 6,412 | 85,314 | 182,842 | Mar 05 |
| Leupin Nicolas | Former Chief Medical Officer | Mar 04 '26 | Sale | 13.31 | 1,100 | 14,636 | 102,979 | Mar 05 |
| Puri Michal Nath | Chief Human Resources Officer | Mar 04 '26 | Sale | 13.31 | 1,100 | 14,636 | 201,322 | Mar 05 |
| Paravasthu Mukund | Chief Operating Officer | Mar 04 '26 | Sale | 13.31 | 5,377 | 71,543 | 116,078 | Mar 05 |
| Weinberg Uri | Chf Medical and Innovation Ofr | Mar 04 '26 | Sale | 13.31 | 6,412 | 85,314 | 267,190 | Mar 05 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.